Assertio Reports Second Quarter 2025 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Assertio Therapeutics (ASRT) Tops Q2 EPS by 10c
August 11, 2025 4:07 PM EDTAssertio Therapeutics (NASDAQ: ASRT) reported Q2 EPS of $0.02, $0.10 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $28.8 million versus the consensus estimate of $27.87 million.
Guidance:
Outlook Update
CEO OGrady said Results through the second quarter are... More
